SCHEMBL31429360

SCHEMBL31429360

O=C(O)c1nn(CC(F)(F)F)c2ncccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.43
ELANE P08246 2/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
METAP2 P50579 2/20 0.41
CFD P00746 2/20 0.39
HTR3A P46098 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
RET P07949 1/20 0.38
KDR P35968 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
BLM P54132 1/20 0.38
AGER Q15109 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19127918 0.85 L3MBTL1 (0.44) KMT2AMEN1L3MBTL1CFDHTR3A
SCHEMBL31429254 0.84 METAP2 (0.44) ELANEL3MBTL1METAP2CFDHTR3A
SCHEMBL1216684 0.82 L3MBTL1 (0.63) KMT2AMEN1L3MBTL1PTGDR2KDM4E
SCHEMBL30744912 0.81 CNR1 (0.45) ELANEKMT2AMEN1L3MBTL1HTR3A
SCHEMBL29805363 0.78 HTR3A (0.55) RAB9AELANEKMT2AMEN1HTR3A
SCHEMBL30587551 0.78 ELANE (0.45) ELANEKMT2AMEN1L3MBTL1PTGDR2
SCHEMBL31429212 0.78 RORC (0.40) RAB9AL3MBTL1METAP2HTR3AKDM4E
SCHEMBL174160 0.76 ATM (0.54) KMT2AMEN1L3MBTL1ATMMAPT
SCHEMBL14584104 0.75 ALDH1A1 (0.50) KMT2AMEN1L3MBTL1PTGDR2KDM4E
SCHEMBL4056268 0.75 RET (0.44) ELANEKMT2AMEN1CFDHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES INC (US) 2025-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE LPL, LIPA, PNLIP RAB9A 3037/4885ELANE 92/4885KMT2A 3811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.